Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Combination treatment using X-rays then ZSTK474 given orally for 8 days
Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode
PubMed PMID: 22948716
Chemical Name: N-methyl-4-(4-(3-(trifluoromethyl)benzamido)phenoxy)picolinamide
PKI-587 stin Targeting Myddosome Signaling in Waldenström'sPKI 587is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K mTOR signaling pathway, with potential antineoplastic activity. Upon intravenous administration, PI3K mTOR kinase inhibitor PKI 587 inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K mTOR. Activation of the PI3K mTOR pathway promotes cell growth, survival,